Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...

Ibrutinib shows similar real-world overall survival outcomes for high-risk and non-high-risk CLL/SLL patients, suggesting cytogenetic risk factors do not affect its efficacy. The study utilized a ...

Abbreviations: BR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy-chain variable region; SLL ...

ORLANDO -- Patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) lived significantly longer without disease progression when treated with the Bruton's ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...

As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...

LBA-3: Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients ORLANDO, ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.